PPD Announces Fourth Quarter and Full Year 2019 Earnings Release Date and Conference Call

February 20, 2020 Off By BusinessWire

WILMINGTON, N.C.–(BUSINESS WIRE)–PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it will release its fourth quarter and full year 2019 results and issue full year 2020 guidance after market close on Wednesday, March 4, 2020. The earnings release and accompanying financial information will be available on the investors section of PPD’s website at https://investors.ppdi.com. The release will be followed by a conference call on Thursday, March 5, 2020, at 8:30 a.m. (U.S. Eastern Time). The conference call can be accessed live by phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560.

Investors and other interested parties also may listen to a live webcast of the conference call by logging onto the presentations page of the investors section of PPD’s website at https://investors.ppdi.com/presentations. A replay of the webcast will be available shortly after the call has concluded. In addition, an audio replay will be available after the call and can be accessed by dialing +1 844 512 2921, or for international callers, +1 412 317 6671. The passcode for the live conference call and the replay is 13698656. The audio replay will be available until Thursday, March 19, 2020.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.

Contacts

Media:

Ned Glascock

+1 910 558 8760

[email protected]

Investors:

+1 910 558 2899

[email protected]